Clinical trial

Nab-P+Cb+PD1 Inhibitors as Neoadjuvant Therapy for Early TNBC

NCT06817525

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2024-11-06

PhasePHASE2

Study timeline

Study start (actual)2024-11-06Date precision: day

Registry last updated2025-12-05

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Triple-negative Breast Cancerunresolved

Interventions

6*Nab-P (d 1)+6*Cb ( d 1)+6*PD1 (d 1)DRUG

6*Nab-P (d 1,8,15)+6*Cb ( d 1)+6*PD1 (d 1)DRUG

Sponsors & collaborators

Henan Cancer Hospitallead sponsor

Mapped research locations

ZhengzhouHenan, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06817525 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.